

G-pen may aid hypoglycemia with type 1 diabetes

22 February 2016



74, and 70 mg/dL, respectively, with maximal increases of 19, 24, and 43 mg/dL post-glucagon administration (P

"Subcutaneous, nonaqueous, ready-to-use G-Pen Mini glucagon may provide an alternative to oral carbohydrates for the management of anticipated, impending, or mild hypoglycemia in adults with type 1 diabetes," the authors write.

Several authors disclosed financial ties to Xeris Pharmaceuticals, the maker of the G-Pen.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

(HealthDay)—Mini-dose glucagon administered using a stable, ready-to-use G-Pen Mini glucagon may be an effective option for mild to moderate hypoglycemia in adults with type 1 diabetes, according to a study published online Feb. 9 in *Diabetes Care*.

Morey W. Haymond, M.D., from the Baylor College of Medicine in Houston, and colleagues evaluated mini-dose glucagon in 12 adults with type 1 [diabetes](#) using a stable, liquid, ready-to-use preparation. Subcutaneous doses of 75, 150, and 300 µg of nonaqueous glucagon were administered and, at 180 minutes, subjects received insulin, followed in 60 minutes by a second identical dose of glucagon.

The researchers found that for the 75-, 150-, and 300-µg doses, mean (fasting glucose concentrations [mg/dL] were 110, 110, and 109, respectively, increasing maximally at 60 minutes by 33, 64, and 95 mg/dL [all P glucose concentrations administered post-insulin were 70,

APA citation: G-pen may aid hypoglycemia with type 1 diabetes (2016, February 22) retrieved 23 April 2021 from <https://medicalxpress.com/news/2016-02-g-pen-aid-hypoglycemia-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.